Vertex Pharmaceuticals Inc (VRTX) Stock Research Report

A company built on one disease

Most people have heard of cystic fibrosis, even if they have never met anyone who lives with it. It is an inherited illness that clogs the lungs with thick mucus and makes every breath harder. In the United States and across much of Europe, most of the people treated for it now take tablets every day that help their lungs work better. Those tablets, in most cases, come from Vertex Pharmaceuticals.

A success like this is rare in medicine, and it has made Vertex a large and wealthy company. It has also tied Vertex to a single disease. In recent years the company has started selling medicines for very different conditions: a gene-editing treatment for inherited blood disorders, a pain medicine that is not an opioid, a drug for a rare hormonal illness. Can Vertex become more than a cystic fibrosis company?

What the Company Does

Vertex makes medicines for serious, often rare, diseases, and nearly all of its money still comes from one of them. Its main cystic fibrosis tablet, sold in the United States as Trikafta, brought in 85.9% of revenue in 2025. In the latest quarter, that tablet, the older cystic fibrosis drugs and a newer version taken once a day together made up 95.1% of revenue.

Patients rarely pay Vertex themselves. In the United States, most sales go to a small number of specialty pharmacies, distributors and large wholesalers. Consider a young woman with cystic fibrosis. Her doctor writes the prescription, a specialty pharmacy sends her the tablets, and the pharmacy pays Vertex, month after month. Abroad, many buyers are hospitals and pharmacies owned or supported by governments.

The newer medicines bring money in differently. Casgevy edits a patient's own genes to treat sickle cell disease and a related blood disorder. It is given only once, in approved treatment centers. Vertex shares this medicine with CRISPR Therapeutics, which takes 40% of the medicine's profits or losses.

Beyond these, Vertex is building a wider set of smaller businesses. It also sells its non-opioid pain medicine. In 2026 it paid about $10.0 billion for Crinetics, which makes a drug for a rare hormonal illness. A kidney treatment is waiting for a decision from regulators. Therapies for type 1 diabetes are further behind. Vertex presents this growing collection as its future; beside cystic fibrosis, each piece is still small.

🔒

Sign in to read the full report

Legal Notes and Methodology

Producer and publisher: Francesco Monterosso · ReasyPort
Financial information reference: 2026-03-31
Legal contact: legal@reasyport.com

Legal Disclaimer

This report is general, non-personalized research provided solely for informational and educational purposes. It is not financial or investment advice, a personalized recommendation, an offer to the public, a solicitation, an instruction to buy, sell or hold a financial instrument, or an invitation to engage in an investment activity. ReasyPort is not an authorised or regulated investment firm and does not provide a MiFID II investment service.

Methodology

This report is based on primary and public sources identified in the report, including issuer filings, annual and interim reports, regulated announcements, investor-relations materials, market data and, where relevant, institutional macroeconomic publications. Facts should be read separately from interpretations, estimates and opinions.

Text, analyses, summaries, translations and charts may be produced with the support of Artificial Intelligence and are subjected to deterministic data and consistency checks before publication. These controls reduce, but cannot eliminate, errors, omissions or incorrect interpretations. Editorial responsibility for publication remains with the producer identified above.

Estimates, updates and independence

ReasyPort View labels, fair values, forecasts, scenarios, price references and other forward-looking statements are editorial estimates or opinions, not facts or trading instructions. They depend on the assumptions, methodology, market price and information available on the stated reference date and may change without notice. The report is not monitored or updated in real time.

Any relationship, compensation, material holding or other circumstance known to ReasyPort that could reasonably impair the objectivity of a report must be disclosed with that report. Questions, corrections and potential conflicts may be reported through the legal contact shown above.

Warnings and liability

Public and primary sources, automated extraction and data providers may contain material errors, omissions, inaccuracies, restatements or delays. Accuracy, completeness and timeliness are therefore not guaranteed, and important information should be checked against the original source before it is used.

To the maximum extent permitted by applicable law, ReasyPort, the author, the publisher and the persons involved in producing the report are not liable for losses arising from decisions made solely in reliance on this report. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.

Investment Risk

Any investment decision should be made independently, if appropriate with the support of a licensed financial adviser. Investments in financial instruments involve risks, including the possible partial or total loss of invested capital.

Research methodology, assumptions and disclosures Meaning of ReasyPort View

Vertex Pharmaceuticals Inc (VRTX) - Stock report